Comparative Pharmacology
Head-to-head clinical analysis: NORETHINDRONE ACETATE versus PROGESTERONE VAGINAL.
Head-to-head clinical analysis: NORETHINDRONE ACETATE versus PROGESTERONE VAGINAL.
NORETHINDRONE ACETATE vs Progesterone (Vaginal)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progestin that suppresses gonadotropin secretion, inhibits ovulation, and induces endometrial thinning. Also binds to progesterone receptors, exerting antiestrogenic effects.
Progesterone binds to progesterone receptors in the reproductive tract, converting proliferative endometrium to secretory endometrium, and reduces gonadotropin secretion, inhibiting ovulation.
Oral, 5 mg once daily for 14 days per cycle, beginning on day 1 of menstrual cycle; for endometriosis, 5 mg daily for 14 days then 10 mg daily for 14 days, then 15 mg daily, or as tolerated up to 15 mg daily continuous.
For progesterone deficiency (e.g., assisted reproductive technology, luteal phase support): 90 mg intravaginally once daily. For secondary amenorrhea: 45 mg intravaginally every other day for up to 12 doses, then 90 mg if needed. For threatened abortion: 200-400 mg intravaginally once or twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 5-8 hours (mean 7.5 hours). Clinically, steady-state is achieved within 2-3 days of daily dosing.
The terminal elimination half-life of progesterone administered vaginally is approximately 5.5 to 6 hours (range: 4.5–8.0 hours) in women with normal renal and hepatic function. This short half-life necessitates twice-daily dosing for sustained effects.
Renal (39-61% as metabolites), biliary/fecal (35-49% as metabolites). Less than 1% excreted unchanged.
Primarily hepatic metabolism; about 50-60% of metabolites are excreted renally as glucuronide conjugates, with approximately 30-40% eliminated via feces. Less than 1% of unchanged progesterone is excreted in urine.
Category D/X
Category A/B
Progestin
Progestin